You are here

  • Home
  • Archive
  • Volume 15, Issue Suppl 2
  • 000103 PACLITAXEL-CARBOPLATIN-GEMCITABINE VS. PACLITAXEL-CARBOPLATIN AS FIRSTLINE TREATMENT OF OVARIAN CANCER: A RANDOMIZED PHASE III GCIG INTERGROUP STUDY (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

Article info

Article menu
Download PDFPDF
Oral Presentations – Thursday, September 29, 2005
000103 PACLITAXEL-CARBOPLATIN-GEMCITABINE VS. PACLITAXEL-CARBOPLATIN AS FIRSTLINE TREATMENT OF OVARIAN CANCER: A RANDOMIZED PHASE III GCIG INTERGROUP STUDY (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)

Authors

Citation

du Bois A, Schroeder W, Jelic S, et al
000103 PACLITAXEL-CARBOPLATIN-GEMCITABINE VS. PACLITAXEL-CARBOPLATIN AS FIRSTLINE TREATMENT OF OVARIAN CANCER: A RANDOMIZED PHASE III GCIG INTERGROUP STUDY (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)
International Journal of Gynecologic Cancer 2005;15:80.
Online issue publication 
December 23, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2005 IGCS